Salix Pharmaceuticals, Ltd. (SLXP)
Q2 2012 Earnings Call
August 8, 2012 5:00 pm ET
Michael Freeman – Associate Vice President, Investor Relations and Corporate Communications
Adam C. Derbyshire – Chief Financial Officer, Executive Vice President-Finance and Administration
Carolyn J. Logan – President and Chief Executive Officer
William P. Forbes – Executive Vice President-Research and Development and Chief Development Officer
Michael Faerm – Credit Suisse
Ami Fadia – UBS Securities LLC
Mario Corso – Caris & Co., Inc.
David A. Amsellem – Piper Jaffray, Inc.
Corey Davis – Jeffries & Co, Inc.
Jim Dawson – Buckingham Research
Annabel Samimy – Stifel, Nicolaus & Co., Inc.
Irina Rivkind – Cantor Fitzgerald Securities
Michael Tong – Wells Fargo Securities LLC
Andrew J. Finkelstein – Susquehanna Financial Group LLP
Liisa A. Bayko – JMP Securities LLC
Scott R. Henry – ROTH Capital Partners LLC
Patricia Banks – DISCERN Securities, Inc.
Gregory D. Fraser – Bank of America/Merrill Lynch
Good afternoon. My name is Jay, and I will be your conference operator today. At this time, I would like to welcome everyone to Salix Pharmaceuticals’ Second Quarter 2012 Earnings Call. All lines have been placed on mute to prevent any background noise. After the speakers’ remarks, there will be a question-and-answer session. (Operator Instructions) Thank you.
Mr. Michael Freeman, Associate Vice President of Investor Relations, you may begin.
Thank you. Good afternoon, and thank you for joining us today. I am Mike Freeman, Associate Vice President of Investor Relations and Corporate Communications for Salix Pharmaceuticals. With me today are Carolyn Logan, President and Chief Executive Officer; Adam Derbyshire, Executive Vice President and Chief Financial Officer; and Bill Forbes, Executive Vice President, Medical and Research and Development, and Chief Development Officer.